Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of SYS6010 Combined With Enlonstobart in the Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

NCT07254585 is registered in ClinicalTrials.gov with CSPC Megalith Biopharmaceutical Co.,Ltd. as lead sponsor.

NCT NCT07254585
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07254585 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Multicenter, Phase II Study to Evaluate the Efficacy and Safety of SYS6010 Combined With Enlonstobart in the Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Lead sponsor
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase
Phase 2
Overall status
Recruiting
Start date
December 18, 2025
Completion date
December 31, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

head and neck squamous cell carcinoma